{"product_id":"cleveland-clinic-2nd-annual-cleveland-clinic-cancer-conference-2026","title":"Cleveland Clinic 2nd Annual Cleveland Clinic Cancer Conference 2026","description":"\u003ch1 data-section-id=\"1d1726z\" data-start=\"0\" data-end=\"54\"\u003eCleveland Clinic 2nd Annual Cleveland Clinic Cancer Conference 2026\u003c\/h1\u003e\r\n\u003cp data-start=\"55\" data-end=\"167\"\u003eMultidisciplinary Oncology Updates in Precision Medicine, Immunotherapy, Hematologic Malignancies \u0026amp; Solid Tumors\u003c\/p\u003e\r\n\u003cp data-start=\"169\" data-end=\"726\"\u003eCancer care continues evolving at extraordinary speed as advances in genomics, immunotherapy, molecular diagnostics, cellular therapy, and precision oncology reshape how clinicians diagnose and treat malignancies across every stage of disease. The \u003cem data-start=\"417\" data-end=\"469\"\u003eCleveland Clinic 2nd Annual Cancer Conference 2026\u003c\/em\u003e delivers a broad, multidisciplinary review of contemporary oncology practice through expert-led discussions covering hematologic malignancies, solid tumors, targeted therapies, palliative medicine, artificial intelligence, and emerging cancer technologies.\u003c\/p\u003e\r\n\u003cp data-start=\"728\" data-end=\"1064\"\u003eBuilt around the theme \u003cstrong data-start=\"751\" data-end=\"795\"\u003e“Innovations in Multidisciplinary Care,”\u003c\/strong\u003e this conference brings together specialists from medical oncology, hematology, radiation oncology, surgical oncology, precision medicine, and supportive care to examine how modern cancer management increasingly depends on integrated, personalized treatment strategies.\u003c\/p\u003e\r\n\u003cp data-start=\"1066\" data-end=\"1100\"\u003eThis educational package includes:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"1101\" data-end=\"1201\"\u003e\r\n \t\u003cli data-section-id=\"1vdca42\" data-start=\"1101\" data-end=\"1124\"\u003e\u003cstrong data-start=\"1103\" data-end=\"1124\"\u003e37 Video Lectures\u003c\/strong\u003e\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1uckpe5\" data-start=\"1125\" data-end=\"1141\"\u003e\u003cstrong data-start=\"1127\" data-end=\"1141\"\u003e1 PDF File\u003c\/strong\u003e\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1m30lbd\" data-start=\"1142\" data-end=\"1167\"\u003e\u003cstrong data-start=\"1144\" data-end=\"1167\"\u003eTotal Size: 5.02 GB\u003c\/strong\u003e\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"i29xz6\" data-start=\"1168\" data-end=\"1201\"\u003e\u003cstrong data-start=\"1170\" data-end=\"1201\"\u003eRelease Date: March 2, 2026\u003c\/strong\u003e\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"1203\" data-end=\"1492\"\u003eHeld at the Margaritaville Hollywood Beach Resort in Florida and simultaneously streamed online, the conference reflects the growing complexity of modern oncology, where treatment decisions increasingly require collaboration across multiple specialties and evolving molecular technologies.\u003c\/p\u003e\r\n\r\n\u003ch2 data-section-id=\"tcg9a9\" data-start=\"1494\" data-end=\"1532\"\u003eThe Shift Toward Precision Oncology\u003c\/h2\u003e\r\n\u003cp data-start=\"1534\" data-end=\"1693\"\u003eOne of the central themes throughout the conference is the continued transition from traditional organ-based cancer treatment toward precision-driven oncology.\u003c\/p\u003e\r\n\u003cp data-start=\"1695\" data-end=\"1737\"\u003eModern oncology increasingly incorporates:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"1738\" data-end=\"1921\"\u003e\r\n \t\u003cli data-section-id=\"1dal7r6\" data-start=\"1738\" data-end=\"1759\"\u003eGenomic profiling\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1n7yrj4\" data-start=\"1760\" data-end=\"1805\"\u003eMinimal residual disease (MRD) monitoring\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"3gegvz\" data-start=\"1806\" data-end=\"1830\"\u003eMolecular biomarkers\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"fml471\" data-start=\"1831\" data-end=\"1853\"\u003eTargeted therapies\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"94ld3u\" data-start=\"1854\" data-end=\"1880\"\u003eCellular immunotherapy\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"m218eu\" data-start=\"1881\" data-end=\"1921\"\u003eAI-assisted clinical decision-making\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"1923\" data-end=\"2029\"\u003eThe course repeatedly emphasizes that many cancers once managed uniformly are now stratified according to:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"2030\" data-end=\"2178\"\u003e\r\n \t\u003cli data-section-id=\"17vw8ql\" data-start=\"2030\" data-end=\"2054\"\u003eMolecular signatures\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1gbmpf8\" data-start=\"2055\" data-end=\"2075\"\u003eDriver mutations\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"74td6g\" data-start=\"2076\" data-end=\"2118\"\u003eTumor microenvironment characteristics\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1gd5gzs\" data-start=\"2119\" data-end=\"2144\"\u003eImmune responsiveness\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1sqe5i6\" data-start=\"2145\" data-end=\"2178\"\u003eTreatment resistance pathways\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"2180\" data-end=\"2270\"\u003eThis shift has fundamentally changed both prognosis assessment and therapeutic sequencing.\u003c\/p\u003e\r\n\r\n\u003ch2 data-section-id=\"1eazwtn\" data-start=\"2272\" data-end=\"2318\"\u003eHematologic Malignancies \u0026amp; Cellular Therapy\u003c\/h2\u003e\r\n\u003cp data-start=\"2320\" data-end=\"2373\"\u003eThe hematologic oncology sessions provide updates on:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"2374\" data-end=\"2538\"\u003e\r\n \t\u003cli data-section-id=\"1dnpy0\" data-start=\"2374\" data-end=\"2406\"\u003eMyeloproliferative neoplasms\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1kjf7qx\" data-start=\"2407\" data-end=\"2442\"\u003eMyelodysplastic syndromes (MDS)\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1j00ihz\" data-start=\"2443\" data-end=\"2475\"\u003eAcute myeloid leukemia (AML)\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"5ei41y\" data-start=\"2476\" data-end=\"2496\"\u003eMultiple myeloma\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1eqpehk\" data-start=\"2497\" data-end=\"2515\"\u003eAL amyloidosis\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1q1mqxw\" data-start=\"2516\" data-end=\"2538\"\u003eCAR-T cell therapy\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"2540\" data-end=\"2681\"\u003eThe discussions examine how advances in molecular genetics and immune-based therapies are rapidly transforming hematologic cancer management.\u003c\/p\u003e\r\n\u003cp data-start=\"2683\" data-end=\"2750\"\u003eOne recurring challenge in hematologic oncology involves balancing:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"2751\" data-end=\"2873\"\u003e\r\n \t\u003cli data-section-id=\"s75h4z\" data-start=\"2751\" data-end=\"2770\"\u003eDisease control\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"q57n4x\" data-start=\"2771\" data-end=\"2793\"\u003eTreatment toxicity\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1asjf5k\" data-start=\"2794\" data-end=\"2820\"\u003eTransplant eligibility\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"rkxp8j\" data-start=\"2821\" data-end=\"2850\"\u003eLong-term quality of life\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1osrvgy\" data-start=\"2851\" data-end=\"2873\"\u003eRelapse prevention\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"2875\" data-end=\"2927\"\u003eparticularly in older or medically complex patients.\u003c\/p\u003e\r\n\u003cp data-start=\"2929\" data-end=\"3117\"\u003eThe CAR-T and cellular therapy lectures explore the expanding role of engineered immune therapies in refractory malignancies and the evolving management of treatment-related complications.\u003c\/p\u003e\r\n\r\n\u003ch2 data-section-id=\"3d1wjb\" data-start=\"3119\" data-end=\"3161\"\u003eGenomics, AI \u0026amp; Personalized Cancer Care\u003c\/h2\u003e\r\n\u003cp data-start=\"3163\" data-end=\"3234\"\u003eThe precision oncology sessions focus heavily on emerging technologies.\u003c\/p\u003e\r\n\u003cp data-start=\"3236\" data-end=\"3251\"\u003eTopics include:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"3252\" data-end=\"3440\"\u003e\r\n \t\u003cli data-section-id=\"wklztg\" data-start=\"3252\" data-end=\"3282\"\u003eGenetic testing strategies\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"99d7ga\" data-start=\"3283\" data-end=\"3322\"\u003eMinimal residual disease monitoring\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"h5vy98\" data-start=\"3323\" data-end=\"3362\"\u003eArtificial intelligence in oncology\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"n69oix\" data-start=\"3363\" data-end=\"3402\"\u003ePrecision oncology case discussions\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1rq113f\" data-start=\"3403\" data-end=\"3440\"\u003ePersonalized therapeutic planning\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"3442\" data-end=\"3609\"\u003eMRD monitoring has become increasingly important because it allows clinicians to detect microscopic residual disease long before radiographic relapse becomes apparent.\u003c\/p\u003e\r\n\u003cp data-start=\"3611\" data-end=\"3673\"\u003eThe AI discussions explore how machine learning may influence:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"3674\" data-end=\"3803\"\u003e\r\n \t\u003cli data-section-id=\"107w9kw\" data-start=\"3674\" data-end=\"3700\"\u003eImaging interpretation\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1bfe2nt\" data-start=\"3701\" data-end=\"3725\"\u003eTreatment prediction\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"16h2g6y\" data-start=\"3726\" data-end=\"3751\"\u003eWorkflow optimization\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"111tq8m\" data-start=\"3752\" data-end=\"3779\"\u003eClinical trial matching\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"97jh7l\" data-start=\"3780\" data-end=\"3803\"\u003ePrognostic modeling\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"3805\" data-end=\"3976\"\u003eAt the same time, the course appropriately acknowledges that integrating AI into oncology practice still presents important ethical, logistical, and validation challenges.\u003c\/p\u003e\r\n\r\n\u003ch2 data-section-id=\"mxw5dp\" data-start=\"3978\" data-end=\"4030\"\u003eLung Cancer: Rapidly Changing Treatment Paradigms\u003c\/h2\u003e\r\n\u003cp data-start=\"4032\" data-end=\"4064\"\u003eThe lung cancer sessions review:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"4065\" data-end=\"4224\"\u003e\r\n \t\u003cli data-section-id=\"ydiof4\" data-start=\"4065\" data-end=\"4097\"\u003eEarly-stage NSCLC management\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"h232oy\" data-start=\"4098\" data-end=\"4126\"\u003eLocally advanced disease\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"w2b658\" data-start=\"4127\" data-end=\"4147\"\u003eMetastatic NSCLC\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1tywc55\" data-start=\"4148\" data-end=\"4174\"\u003eSmall cell lung cancer\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"hw8448\" data-start=\"4175\" data-end=\"4224\"\u003eSurgical challenges after neoadjuvant therapy\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"4226\" data-end=\"4279\"\u003eThoracic oncology continues evolving rapidly through:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"4280\" data-end=\"4414\"\u003e\r\n \t\u003cli data-section-id=\"1a6v2os\" data-start=\"4280\" data-end=\"4310\"\u003eImmunotherapy combinations\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"2e4k65\" data-start=\"4311\" data-end=\"4340\"\u003eMolecular-targeted agents\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1byyn3r\" data-start=\"4341\" data-end=\"4373\"\u003eNeoadjuvant systemic therapy\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"qe1dl1\" data-start=\"4374\" data-end=\"4414\"\u003eBiomarker-driven treatment selection\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"4416\" data-end=\"4487\"\u003eClinical decision-making becomes increasingly complex when determining:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"4488\" data-end=\"4598\"\u003e\r\n \t\u003cli data-section-id=\"19ocz1o\" data-start=\"4488\" data-end=\"4507\"\u003eSurgical timing\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"13ohk8s\" data-start=\"4508\" data-end=\"4528\"\u003eAdjuvant therapy\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1oh4ht4\" data-start=\"4529\" data-end=\"4561\"\u003eMolecular testing priorities\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1m1s2og\" data-start=\"4562\" data-end=\"4598\"\u003eSequencing of systemic treatment\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"4600\" data-end=\"4689\"\u003eparticularly in patients with multiple targetable mutations or mixed histologic features.\u003c\/p\u003e\r\n\r\n\u003ch2 data-section-id=\"2rln5h\" data-start=\"4691\" data-end=\"4735\"\u003eSupportive Oncology \u0026amp; Palliative Medicine\u003c\/h2\u003e\r\n\u003cp data-start=\"4737\" data-end=\"4911\"\u003eThe palliative care sessions are especially valuable because modern oncology increasingly recognizes symptom management as a core component of comprehensive cancer treatment.\u003c\/p\u003e\r\n\u003cp data-start=\"4913\" data-end=\"4928\"\u003eTopics include:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"4929\" data-end=\"5077\"\u003e\r\n \t\u003cli data-section-id=\"19bg8vg\" data-start=\"4929\" data-end=\"4948\"\u003eCancer cachexia\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1rdloza\" data-start=\"4949\" data-end=\"4971\"\u003eFatigue management\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1s24zqz\" data-start=\"4972\" data-end=\"4996\"\u003eNeuropathy treatment\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1pf14g1\" data-start=\"4997\" data-end=\"5031\"\u003eBenzodiazepine use in oncology\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"5aespj\" data-start=\"5032\" data-end=\"5077\"\u003eIntegrative therapies such as acupuncture\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"5079\" data-end=\"5239\"\u003eThe course appropriately emphasizes that supportive oncology is not limited to end-of-life care, but instead plays a major role throughout the cancer continuum.\u003c\/p\u003e\r\n\u003cp data-start=\"5241\" data-end=\"5345\"\u003eIn practice, many treatment-limiting complications arise not directly from cancer progression, but from:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"5346\" data-end=\"5469\"\u003e\r\n \t\u003cli data-section-id=\"1i5jp7l\" data-start=\"5346\" data-end=\"5369\"\u003eNutritional decline\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1i0n5y9\" data-start=\"5370\" data-end=\"5394\"\u003eNeuropathic toxicity\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"xt4wgc\" data-start=\"5395\" data-end=\"5423\"\u003eFunctional deterioration\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"54knxk\" data-start=\"5424\" data-end=\"5450\"\u003ePsychological distress\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1bs8dfn\" data-start=\"5451\" data-end=\"5469\"\u003eSymptom burden\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch2 data-section-id=\"47cn8o\" data-start=\"5471\" data-end=\"5515\"\u003eNovel Therapies \u0026amp; Emerging Drug Platforms\u003c\/h2\u003e\r\n\u003cp data-start=\"5517\" data-end=\"5613\"\u003eThe novel therapeutics section reviews several rapidly evolving treatment modalities, including:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"5614\" data-end=\"5775\"\u003e\r\n \t\u003cli data-section-id=\"ftetla\" data-start=\"5614\" data-end=\"5649\"\u003eAntibody-drug conjugates (ADCs)\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1mlptf6\" data-start=\"5650\" data-end=\"5670\"\u003eRNA therapeutics\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1wkb16p\" data-start=\"5671\" data-end=\"5693\"\u003eCellular therapies\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1qzuso5\" data-start=\"5694\" data-end=\"5727\"\u003eOrgan-preservation strategies\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1lp3f0o\" data-start=\"5728\" data-end=\"5775\"\u003eClinical complete response (cCR) assessment\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"5777\" data-end=\"5893\"\u003eAntibody-drug conjugates have become one of the most important developments in modern oncology because they combine:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"5894\" data-end=\"5974\"\u003e\r\n \t\u003cli data-section-id=\"x6svy5\" data-start=\"5894\" data-end=\"5916\"\u003eTarget specificity\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"vcs9cs\" data-start=\"5917\" data-end=\"5939\"\u003eCytotoxic delivery\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"fst1as\" data-start=\"5940\" data-end=\"5974\"\u003eImproved therapeutic precision\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"5976\" data-end=\"6129\"\u003eThe conference also explores how RNA-based therapeutics may reshape future cancer treatment through highly individualized molecular targeting approaches.\u003c\/p\u003e\r\n\r\n\u003ch2 data-section-id=\"1t3xso0\" data-start=\"6131\" data-end=\"6174\"\u003eGynecologic Oncology, Sarcoma \u0026amp; Melanoma\u003c\/h2\u003e\r\n\u003cp data-start=\"6176\" data-end=\"6212\"\u003eThe solid tumor discussions address:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"6213\" data-end=\"6317\"\u003e\r\n \t\u003cli data-section-id=\"upsdp0\" data-start=\"6213\" data-end=\"6236\"\u003eGynecologic cancers\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"h6dedk\" data-start=\"6237\" data-end=\"6248\"\u003eSarcoma\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"iror28\" data-start=\"6249\" data-end=\"6261\"\u003eMelanoma\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"i7zow3\" data-start=\"6262\" data-end=\"6287\"\u003eHead and neck cancers\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"vxsu7q\" data-start=\"6288\" data-end=\"6317\"\u003eNon-melanoma skin cancers\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"6319\" data-end=\"6468\"\u003eThe sarcoma sessions are particularly relevant because sarcoma management often requires highly specialized multidisciplinary coordination involving:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"6469\" data-end=\"6568\"\u003e\r\n \t\u003cli data-section-id=\"13h8ld8\" data-start=\"6469\" data-end=\"6490\"\u003eSurgical oncology\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1jyfjgb\" data-start=\"6491\" data-end=\"6513\"\u003eRadiation oncology\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1mtm5kl\" data-start=\"6514\" data-end=\"6537\"\u003eMolecular pathology\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"t569lw\" data-start=\"6538\" data-end=\"6568\"\u003eSystemic therapy selection\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"6570\" data-end=\"6711\"\u003eMeanwhile, melanoma therapy continues evolving through increasingly sophisticated immunotherapy combinations and biomarker-guided approaches.\u003c\/p\u003e\r\n\r\n\u003ch2 data-section-id=\"1tglsxe\" data-start=\"6713\" data-end=\"6741\"\u003eGastrointestinal Oncology\u003c\/h2\u003e\r\n\u003cp data-start=\"6743\" data-end=\"6775\"\u003eThe GI oncology sessions review:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"6776\" data-end=\"6934\"\u003e\r\n \t\u003cli data-section-id=\"1xp369r\" data-start=\"6776\" data-end=\"6809\"\u003eEarly-onset colorectal cancer\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"vsvlg0\" data-start=\"6810\" data-end=\"6838\"\u003eGastroesophageal cancers\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"5uv7rk\" data-start=\"6839\" data-end=\"6870\"\u003eColorectal liver metastases\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1v8qxox\" data-start=\"6871\" data-end=\"6894\"\u003eSurgical innovation\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1bd1ueq\" data-start=\"6895\" data-end=\"6934\"\u003eShifting systemic therapy paradigms\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"6936\" data-end=\"7093\"\u003eEarly-onset GI cancers have become an especially important area of investigation as incidence rises in younger populations without traditional risk profiles.\u003c\/p\u003e\r\n\u003cp data-start=\"7095\" data-end=\"7116\"\u003eThe lectures explore:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"7117\" data-end=\"7232\"\u003e\r\n \t\u003cli data-section-id=\"1wylyov\" data-start=\"7117\" data-end=\"7143\"\u003eGenetic predisposition\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"15fb76g\" data-start=\"7144\" data-end=\"7170\"\u003eScreening implications\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1l0uc1a\" data-start=\"7171\" data-end=\"7196\"\u003eMolecular differences\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"4og9s7\" data-start=\"7197\" data-end=\"7232\"\u003eEvolving therapeutic strategies\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch2 data-section-id=\"1k3kjl8\" data-start=\"7234\" data-end=\"7258\"\u003eBreast Cancer Updates\u003c\/h2\u003e\r\n\u003cp data-start=\"7260\" data-end=\"7297\"\u003eThe breast oncology section examines:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"7298\" data-end=\"7454\"\u003e\r\n \t\u003cli data-section-id=\"1wszf1r\" data-start=\"7298\" data-end=\"7325\"\u003eBreast surgery advances\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"c499q1\" data-start=\"7326\" data-end=\"7356\"\u003eRadiation oncology updates\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1qzw4hf\" data-start=\"7357\" data-end=\"7386\"\u003eAdjuvant systemic therapy\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1rhj7aa\" data-start=\"7387\" data-end=\"7425\"\u003eMetastatic breast cancer treatment\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1rrns6g\" data-start=\"7426\" data-end=\"7454\"\u003eADCs in advanced disease\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"7456\" data-end=\"7561\"\u003eBreast oncology remains one of the fastest-changing areas in cancer medicine due to rapid integration of:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"7562\" data-end=\"7681\"\u003e\r\n \t\u003cli data-section-id=\"fml471\" data-start=\"7562\" data-end=\"7584\"\u003eTargeted therapies\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"jn2ipl\" data-start=\"7585\" data-end=\"7622\"\u003eHER2-directed treatment evolution\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"f8i8b4\" data-start=\"7623\" data-end=\"7657\"\u003ePrecision endocrine strategies\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1l91xno\" data-start=\"7658\" data-end=\"7681\"\u003eMolecular profiling\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch2 data-section-id=\"1tavfzq\" data-start=\"7683\" data-end=\"7724\"\u003eMultidisciplinary Tumor Board Learning\u003c\/h2\u003e\r\n\u003cp data-start=\"7726\" data-end=\"7814\"\u003eA major strength of the conference is its extensive use of tumor board case discussions.\u003c\/p\u003e\r\n\u003cp data-start=\"7816\" data-end=\"7922\"\u003eThese sessions simulate real-world oncology decision-making where management often depends on integrating:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"7923\" data-end=\"8066\"\u003e\r\n \t\u003cli data-section-id=\"evw4d8\" data-start=\"7923\" data-end=\"7943\"\u003eImaging findings\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"o9p98d\" data-start=\"7944\" data-end=\"7972\"\u003ePathology interpretation\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"fbi6v0\" data-start=\"7973\" data-end=\"7989\"\u003eGenomic data\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1vaouuf\" data-start=\"7990\" data-end=\"8014\"\u003eSurgical feasibility\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1jk0id2\" data-start=\"8015\" data-end=\"8037\"\u003eRadiation planning\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1s2cfck\" data-start=\"8038\" data-end=\"8066\"\u003eSystemic therapy options\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"8068\" data-end=\"8201\"\u003eThe tumor board format highlights the reality that modern oncology care is increasingly collaborative rather than specialty-isolated.\u003c\/p\u003e\r\n\r\n\u003ch2 data-section-id=\"9jcuf2\" data-start=\"8203\" data-end=\"8235\"\u003eReal-World Clinical Relevance\u003c\/h2\u003e\r\n\u003cp data-start=\"8237\" data-end=\"8274\"\u003eThe conference repeatedly emphasizes:\u003c\/p\u003e\r\n\r\n\u003cul data-start=\"8275\" data-end=\"8467\"\u003e\r\n \t\u003cli data-section-id=\"1ao7shp\" data-start=\"8275\" data-end=\"8315\"\u003eEvidence-based treatment integration\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1u6axw1\" data-start=\"8316\" data-end=\"8365\"\u003eTranslating clinical trial data into practice\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"sd7jps\" data-start=\"8366\" data-end=\"8398\"\u003eEmerging technology adoption\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"vu6f4r\" data-start=\"8399\" data-end=\"8434\"\u003ePersonalized treatment planning\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1608q21\" data-start=\"8435\" data-end=\"8467\"\u003eSupportive care optimization\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"8469\" data-end=\"8645\"\u003eImportantly, the course avoids focusing solely on theoretical advances and instead addresses how clinicians apply rapidly changing oncology data in everyday patient management.\u003c\/p\u003e\r\n\r\n\u003ch2 data-section-id=\"xydb7h\" data-start=\"8647\" data-end=\"8665\"\u003eWhat’s Included\u003c\/h2\u003e\r\n\u003cul data-start=\"8666\" data-end=\"8965\"\u003e\r\n \t\u003cli data-section-id=\"1togwgy\" data-start=\"8666\" data-end=\"8696\"\u003e37 oncology video lectures\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"3cflkd\" data-start=\"8697\" data-end=\"8711\"\u003e1 PDF file\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"8spxmx\" data-start=\"8712\" data-end=\"8735\"\u003eTotal size: 5.02 GB\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1tj5yap\" data-start=\"8736\" data-end=\"8783\"\u003ePrecision oncology and genomics discussions\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"piiwyz\" data-start=\"8784\" data-end=\"8818\"\u003eHematologic malignancy updates\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1vfmyqb\" data-start=\"8819\" data-end=\"8878\"\u003eLung, breast, GI, gynecologic, and skin cancer sessions\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"1ipuhvi\" data-start=\"8879\" data-end=\"8914\"\u003eCAR-T and novel therapy reviews\u003c\/li\u003e\r\n \t\u003cli data-section-id=\"ymbhew\" data-start=\"8915\" data-end=\"8965\"\u003eMultidisciplinary tumor board case discussions\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch2 data-section-id=\"1uqeci3\" data-start=\"8967\" data-end=\"8994\"\u003eFinal Expert Perspective\u003c\/h2\u003e\r\n\u003cp data-start=\"8996\" data-end=\"9323\"\u003eModern oncology is increasingly defined by precision medicine, multidisciplinary collaboration, and rapidly evolving therapeutic technologies. Molecular diagnostics, cellular therapies, immunotherapy combinations, and AI-assisted clinical tools are reshaping how clinicians approach both common and highly complex malignancies.\u003c\/p\u003e\r\n\u003cp data-start=\"9325\" data-end=\"9823\"\u003eThe \u003cem data-start=\"9329\" data-end=\"9381\"\u003eCleveland Clinic 2nd Annual Cancer Conference 2026\u003c\/em\u003e provides a broad and clinically relevant review of these developments through expert-led discussions spanning hematologic malignancies, solid tumors, supportive oncology, precision medicine, and emerging therapeutic strategies. For oncologists, hematologists, radiation specialists, and multidisciplinary cancer care professionals, this conference offers a valuable overview of contemporary oncology practice and future treatment directions.\u003c\/p\u003e\r\n\u003cstrong\u003eTopics:\u003c\/strong\u003e\r\n\u003ctable cellspacing=\"0\" cellpadding=\"0\"\u003e\r\n\u003ctbody\u003e\r\n\u003ctr\u003e\r\n\u003ctd colspan=\"2\" bgcolor=\"#CCCCCC\"\u003e\u003cstrong\u003eSession 1 – Updates and State of the Art Therapy in Hematologic Malignancies\u003c\/strong\u003e\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd width=\"878\"\u003eAdvances in the Management of Myeloproliferative Neoplasm\u003c\/td\u003e\r\n\u003ctd width=\"378\"\u003eYehuda Galili, MD\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003eRecent Advances in MDS and AML: What’s Practice Changing?\u003c\/td\u003e\r\n\u003ctd\u003eAkriti Jain, MD\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003eAdvances in the Management of Myeloma\/AL Amyloidosis\u003c\/td\u003e\r\n\u003ctd\u003eJack Khouri, MD\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003eTumor Boards Case Panels\u003c\/td\u003e\r\n\u003ctd\u003eBetty Hamilton, MD; Alex Mejia Garcia, MD\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd colspan=\"2\" bgcolor=\"#CCCCCC\"\u003e\u003cstrong\u003eSession 2 – Genomics\/Precision Oncology\u003c\/strong\u003e\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003eGenetic Testing: What Oncologists Should Know\u003c\/td\u003e\r\n\u003ctd\u003eSara Rhode, MS, CGC\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003eThe Future of AI in Cancer Care\u003c\/td\u003e\r\n\u003ctd\u003eAli Zarrinpar, MD, PhD\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003eThe Power of Minimal Residual Disease Monitoring in Personalized Cancer Care\u003c\/td\u003e\r\n\u003ctd\u003eShlomo Koyfman, MD\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003ePrecision Oncology Case Presentation and Panel Discussion\u003c\/td\u003e\r\n\u003ctd\u003eJacob Miller, MD\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd colspan=\"2\" bgcolor=\"#CCCCCC\"\u003e\u003cstrong\u003eSession 3 – Updates and State of the Art Therapy in Lung Cancer\u003c\/strong\u003e\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003eSurgical Challenges After Neo-Adjuvant Therapy\u003c\/td\u003e\r\n\u003ctd\u003eMonisha Sudarshan, MD, MPH\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003eTreatment of Early-Stage and Locally Advanced NSCLC\u003c\/td\u003e\r\n\u003ctd\u003eSuresh S. Ramalingam, MD\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003eSpecial Issues in Managing Metastatic NSCLC\u003c\/td\u003e\r\n\u003ctd\u003eKhaled Hassan, MD\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003eCurrent Management of Small Cell Lung Cancer\u003c\/td\u003e\r\n\u003ctd\u003eLukas Delasos, DO\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003eTumor Boards Case Panels\u003c\/td\u003e\r\n\u003ctd\u003eKhaled Hassan, MD; Diana Saravia, MD\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd colspan=\"2\" bgcolor=\"#CCCCCC\"\u003e\u003cstrong\u003eSession 4 – Key Issues in Palliative Care\u003c\/strong\u003e\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003eCancer Related Anorexia-Cachexia Syndrome and Cancer Related Fatigue: Evidence Based Management and Emerging Treatments\u003c\/td\u003e\r\n\u003ctd\u003eNivia Ruiz, MD\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003eAcupuncture’s Role in Cancer-Related Symptom Management\u003c\/td\u003e\r\n\u003ctd\u003eThuy Nguyen, DAOM, LAc\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003eBenzodiazepines: Friend or Foe?\u003c\/td\u003e\r\n\u003ctd\u003eKaleena Chilcote, MD\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003eCancer Therapy-Induced Neuropathy Management\u003c\/td\u003e\r\n\u003ctd\u003eRenato Samala, MD\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003eTumor Boards Case Panels\u003c\/td\u003e\r\n\u003ctd\u003eLaura Shoemaker, DO\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd colspan=\"2\" bgcolor=\"#CCCCCC\"\u003e\u003cstrong\u003eSession 5 – Novel Therapies\u003c\/strong\u003e\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003eAntibody Drug Conjugate: Innocent Bystander?\u003c\/td\u003e\r\n\u003ctd\u003eWen Wee Ma, MBBS\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003eCAR-T Cells and Cellular Therapy\u003c\/td\u003e\r\n\u003ctd\u003ePaolo Caimi, MD\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003eInnovations in Anti-Cancer RNA Therapeutics\u003c\/td\u003e\r\n\u003ctd\u003eNatalie Silver, MD\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003eWhen to Watch and Wait vs. Refer to Surgery: Best Practices for Defining cCR After TNT\u003c\/td\u003e\r\n\u003ctd\u003eEmre Gorgun, MD\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003eTumor Boards Case Panels\u003c\/td\u003e\r\n\u003ctd\u003eWen Wee Ma, MBBS; Natalie Silver, MD\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd colspan=\"2\" bgcolor=\"#CCCCCC\"\u003e\u003cstrong\u003eSession 6 – Updates and State of the Art Therapy in Selected Solid Tumors\u003c\/strong\u003e\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003eMultidisciplinary Management of Gynecologic Cancers\u003c\/td\u003e\r\n\u003ctd\u003eRobert DeBernardo, MD\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003eAdvancing Sarcoma Therapy: Integrating Immunotherapy, Cellular Strategies and Targeted Payloads\u003c\/td\u003e\r\n\u003ctd\u003eDale Shepard, MD, PhD\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003eMelanoma\u003c\/td\u003e\r\n\u003ctd\u003eJames Isaacs, MD\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003eState of the Art Therapy in Head\/Neck and Non-Melanoma Skin Cancers: Updates in Particle Therapy and Perioperative Immunotherapy\u003c\/td\u003e\r\n\u003ctd\u003eJacob Miller, MD\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003eTumor Boards Case Panels\u003c\/td\u003e\r\n\u003ctd\u003eRobert DeBernardo, MD; Sudha Amarnath, MD\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd colspan=\"2\" bgcolor=\"#CCCCCC\"\u003e\u003cstrong\u003eSession 7 – Updates and State of the Art Therapy in GI Cancers\u003c\/strong\u003e\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003eEarly-Onset Colorectal and Other GI Cancers: Implications for Diagnosis and Treatment\u003c\/td\u003e\r\n\u003ctd\u003eAlok Khorana, MD\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003eNovel Surgical Strategies in Colorectal Liver Metastases\u003c\/td\u003e\r\n\u003ctd\u003eFederico Aucejo, MD\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003eShifting Treatment Paradigms in Gastro-Esophageal Cancers\u003c\/td\u003e\r\n\u003ctd\u003eSuneel Kamath, MD\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003eTumor Boards Case Panels\u003c\/td\u003e\r\n\u003ctd\u003eMatthew Walsh, MD; Alok Khorana, MD\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd colspan=\"2\" bgcolor=\"#CCCCCC\"\u003e\u003cstrong\u003eSession 8 – Breast Cancer\u003c\/strong\u003e\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003eBreast Surgery Update\u003c\/td\u003e\r\n\u003ctd\u003eStephen Grobmyer, MD\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003eBreast Radiation Oncology Updates\u003c\/td\u003e\r\n\u003ctd\u003ePraveen Pendyala, MD\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003eAdvances in Adjuvant Therapy for Breast Cancer\u003c\/td\u003e\r\n\u003ctd\u003eErin Roesch, MD\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003eLatest Updates on the Management of Metastatic Breast Cancer: Antibody -Drug Conjugates for Advanced Stage Disease\u003c\/td\u003e\r\n\u003ctd\u003eRita Nanda, MD\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003eTumor Boards Case Panels\u003c\/td\u003e\r\n\u003ctd\u003eMegan Kruse, MD; Stephen Grobmyer, MD\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003c\/tbody\u003e\r\n\u003c\/table\u003e","brand":"Amboss","offers":[{"title":"Default Title","offer_id":42954732830818,"sku":"MED-AMB08967","price":30.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/Meetings-By-Mail-Cleveland-Clinic-2nd-Annual-Cleveland-Clinic-Cancer-Conference-2026.jpg?v=1779383348","url":"https:\/\/meducourse.com\/products\/cleveland-clinic-2nd-annual-cleveland-clinic-cancer-conference-2026","provider":"Meducourse","version":"1.0","type":"link"}